Edwards' pharma attack used bogus stats

When John Edwards knocked drug companies for spending "twice as much" on marketing and administration as on research, he perpetuated a myth popular amongst pharma naysayers, Fortune magazine says. With only 21 percent of Americans approving Big Pharma's performance (down from 60 percent 10 years ago), it's no wonder people are ready to believe.

The erroneous stat? Lumping marketing and admin together. That line item doesn't really show how much companies spend on selling their products. It includes stuff like office leases, for example. The real numbers, Fortune says? Drug makers spent $55 billion on research in 2006, compared with $12 billion on sales, promotions, and ads.

- read the report in Fortune

Related Articles:
Edwards pledges limits on DTC ads. Report
Final FDA bill lacks new DTC oversight. Report
10 reforms for drug advertising. Report
Does the FDA do enough to regulate drug ads? Report

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.